

Impact of weight loss on treatment interruption and unplanned hospital admission in head and neck cancer patients undergoing curative (chemo)-radiotherapy in Hong Kong

Ying-Chu Choi, Po-Chung Chan, Ka-Wai Alice Cheung, Jia-Jie Huang, Kwok-Leung Aray Wong, Johannes Döscher, Tai-Chung Lam

Angaben zur Veröffentlichung / Publication details:

Choi, Ying-Chu, Po-Chung Chan, Ka-Wai Alice Cheung, Jia-Jie Huang, Kwok-Leung Aray Wong, Johannes Döscher, and Tai-Chung Lam. 2023. "Impact of weight loss on treatment interruption and unplanned hospital admission in head and neck cancer patients undergoing curative (chemo)-radiotherapy in Hong Kong." *Supportive Care in Cancer* 31 (8): 487. <https://doi.org/10.1007/s00520-023-07952-8>.

Nutzungsbedingungen / Terms of use:

licgercopyright

Dieses Dokument wird unter folgenden Bedingungen zur Verfügung gestellt: / This document is made available under these conditions:

Deutsches Urheberrecht

Weitere Informationen finden Sie unter: / For more information see:

<https://www.uni-augsburg.de/de/organisation/bibliothek/publizieren-zitieren-archivieren/publiz/>



Impact of weight loss on treatment interruption and unplanned hospital admission in head and neck cancer patients undergoing curative (chemo)-radiotherapy in Hong Kong

Ying-Chu Choi¹ · Po-Chung Chan² · Ka-Wai Alice Cheung² · Jia-Jie Huang³ · Kwok-Leung Aray Wong² · Johannes Doescher⁴ · Tai-Chung Lam⁵

Abstract

Purpose Malnutrition is highly prevalent in head and neck cancer (HNC) patients, with weight loss being one of the major nutritional indicators. The objective of this study was to investigate the impact of weight loss on treatment interruptions and unplanned hospital admissions in HNC patients undergoing radiotherapy (RT) with or without chemotherapy.

Methods In this retrospective cohort study, consecutive HNC patients who started RT between January 2011 and December 2019 were included. Data from a total of 1086 subjects with 747 (68.8%) nasopharyngeal carcinomas (NPCs) and 31.2% ($N=339$) non-NPC patients were analysed. Body weight (BW) was measured before, during, and after RT treatment. Factors associated with $\geq 10\%$ weight loss, treatment interruption, and unplanned admissions were analysed using multivariate logistic regression.

Results The prevalence of $\geq 10\%$ weight loss was 26.8% ($N=288$), with 32.7% ($N=243$) in NPC and 13.5% ($N=45$) in non-NPC patients. The prevalence of RT delay in patients with $\geq 10\%$ vs. $<10\%$ weight loss was 6.2% vs. 7.0% ($p=0.668$) in NPC patients and 42.2% vs. 50.5% ($p=0.300$) in non-NPC patients. The prevalence of unplanned admissions in patients with $\geq 10\%$ vs. $<10\%$ weight loss was 51.9% vs. 25.3% ($p<0.001$) in NPC patients and 68.9% vs. 27.0% ($p<0.001$) in non-NPC patients.

Conclusion In our study, $\geq 10\%$ weight loss was found to be associated with a higher rate of unplanned admissions but not with RT delay or chemotherapy interruption. Clinical implications: With the knowledge of the impact of weight loss on hospital admissions and the characteristics of patients with weight loss, nutritional intervention can be effectively focused on the stratification of patients for intensive nutritional support to reduce weight loss.

Keywords Head and neck cancer · Weight loss · Treatment interruption · Unplanned hospital admission · Nutrition · NPC · Non-NPC

Introduction

Head and neck cancers (HNCs) represent the sixth most common cancer category worldwide, with 93,193 new cases and 418,982 deaths in 2020 [1]. HNC treatment includes a single modality of surgery or radiotherapy (RT) alone with a disease eradication and organ preservation approach and, for locally advanced disease, multimodality treatment with a combination of surgery and RT with or without chemotherapy [2–4]. Patients who receive radical RT frequently experience difficulties in eating and drinking, leading to inadequate fluid and nutrition intake and consequently resulting in malnutrition and weight loss. Weight loss $>5\%$ has been defined as critical weight loss and was found to be a major prognostic factor for inferior treatment outcomes and

✉ Ying-Chu Choi
choipenny628@gmail.com

¹ Department of Dietetics, Tuen Mun Hospital, Hong Kong, China

² Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China

³ Quality and Services Department, Tuen Mun Hospital, Hong Kong, China

⁴ Department of Otolaryngology, Augsburg University Hospital, Augsburg, Germany

⁵ Department of Clinical Oncology, University of Hong Kong, Hong Kong, China

poor survival in HNC patients [5–11]. Studies have shown that the prevalence of >5% weight loss ranges from 14 to 32% before and 32 to 54% after HNC treatment [11–14]. Critical weight loss was also found to be associated with adverse outcomes, including increased treatment toxicities and decreased treatment response [15, 16], increased enteral feeding dependence [17], unplanned hospital admissions [18], and worse survival outcomes [19].

Studies have demonstrated that treatment interruptions detrimentally impact treatment outcomes, including increased loco-region failure, increased relapse rate, and poor survival [12, 20–22]. Meng et al. showed that weight loss was correlated with treatment interruption in locally advanced nasopharyngeal carcinoma (NPC) patients [23].

In cancer care, unplanned hospital admissions during and after treatment are common, particularly in HNC patients [24]. Unplanned hospital admissions impose a heavy economic burden on the health care system and negatively impact patients' quality of life. The impact of nutritional support on reducing unplanned hospital admissions in HNC patients has been reported in several studies [25–28]. High weight loss during RT was associated with increased hospital admission [9]. Therefore, knowledge of the prevalence of weight loss and its association with treatment interruption and unplanned hospital admissions should be evaluated for HNC patients undergoing (chemo)RT. This knowledge is necessary for developing strategies to improve the treatment outcomes of HNC patients.

Materials and methods

Study subjects

This retrospective cohort study included consecutive newly diagnosed adult HNC patients who were started on curative-intent RT with or without chemotherapy during the period of 1 January 2011 to 31 December 2019. These HNC patients were referred to the dietitian for nutrition support under the blanket referral policy in our centre. Patients with metastatic disease, double primary, cancer recurrence or progressive disease, cancer of unknown primary, cancer of the ear, thyroid cancer, and lymphoma; patients who did not complete the planned treatment; and patients who died during treatment were excluded. Approval was obtained from the ethics committee of New Territories West Cluster Hospital Cluster Research Ethics Committee/Institutional Review Board of Hospital Authority in Hong Kong. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

Data collection

Data were collected retrospectively. Demographic data, including age, sex, social history, smoking, and drinking habits, were collected from dietetic records. Clinical characteristics and treatment outcomes, including diagnosis, staging, treatment modality, chemotherapy and RT regimen, and hospital admissions, were collected from electronic medical records. Nutrition data, including BW, height, number of dietitian outpatient consultations, and feeding tube placement, were obtained from dietetic and oncology records. In our centre, feeding tube placement was mainly proactive in our non-NPC patients as most of these patients already had their feeding tube placed at diagnosis or after surgery, and reactive in our NPC patients. Feeding tube placement was defined as patient once had a feeding tube placed during their treatment regardless of whether it was used for supplementing oral feeding or solely tube feeding. In addition, a new nutrition program was implemented in 2013 where all HNC patients received intensive nutrition support with weekly or bi-weekly dietitian contact before and during treatment.

Outcome variables

The primary outcomes were weight loss <10% and ≥10% at the end of RT treatment, RT delay for more than 2 days of the prescribed schedule, and unplanned hospital admissions from the beginning of concomitant chemoRT or RT until 1 month after the end of RT.

BW in kilograms (kg) and height in metres (m) were routinely measured and recorded in our oncology and dietetic clinics before, during, and after treatment. Weight loss was defined and calculated as the difference between the weight before treatment and the weight at the end of treatment. The calculation is given as follows:

Percentage weight loss at the end of RT treatment = $[(\text{BW at the end of RT treatment} - \text{BW at the beginning of treatment}) \div \text{BW at the beginning of treatment} \times 100]$

Weight loss ≥10% at the end of RT treatment was chosen as the cut-off of high weight loss according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5 [29]. Weight loss 5–10% during treatment was also included as a variable as in our clinical practice it was considered as moderate weight loss and in our experience patients with early weight loss was commonly prone to high weight loss as the treatment progressed. Body mass index (BMI) was calculated as $\text{BMI} = \text{BW (kg)} / \text{Height (m)}^2$. BMI cut-offs were categorized as underweight when BMI was < 18.5 kg/m², normal weight when BMI was between 18.5 and 24.9 kg/m², and obese

when BMI was $\geq 25 \text{ kg/m}^2$ [30]. The mean imputation method was used for missing BW data to provide consistent data. The time points for BW data were pretreatment, weekly during RT, and at the end of RT treatment. BW and BMI were recorded to the nearest 0.1 kg/m^2 .

Treatment interruption: RT delay

Patients were treated with radical RT using volumetric modulated arc therapy (VMAT) with or without chemotherapy. The total dose ranged from 50 to 74 Gy and consisted of 5–6 fractions per week of 2–2.5 Gy per fraction administered to the primary tumour and, if needed, to neck nodes either bilaterally or unilaterally. RT treatment duration was the time from the first day to the last day of RT. RT delay was defined as delay for more than 2 days of the originally planned treatment time according to the guidelines from the Royal College of Radiologists [31].

Unplanned hospital admissions

Unplanned hospital admissions were defined as any unplanned hospital admission requiring inpatient care for more than 24 h, from the beginning of concomitant chemoRT until 1 month after the end of RT treatment. Reasons for admission were categorized as nutrition-related and nonnutrition-related. Nutrition-related admissions included rehydration, poor oral intake, dysphagia, insertion of feeding tube, feeding tube-related causes, and management of eating- or nutrition-related symptoms. In our centre, feeding tube placement was reactive for NPC patients and mostly prophylactic for non-NPC patients, as non-NPC patients often had feeding tubes placed during surgery or at the time of diagnosis and kept until completion of RT treatment.

Statistical methodology

Categorical variables were compared using the chi-square test. Univariate logistic regression was performed to test the association between each independent variable and adverse outcomes, including treatment interruption and unplanned hospital admissions. Independent variables included RT delay, chemotherapy as planned, and unplanned hospital admissions. Variables with a significant association shown in univariate analysis were entered into multivariate analysis logistic regression. A p value of <0.05 was considered to indicate statistical significance. Statistical Package for the Social Sciences (SPSS) software version 27 was used for the statistical analysis.

Results

Patient characteristics

A total of 1086 patients were included, with 747 (68.8%) NPC and 339 (31.2%) non-NPC patients. There were five missing data where BW was not available in our NPC patients for unknown reason. The demographics and characteristics of the patients are shown in Table 1. Locally advanced stage III and IV diseases comprised 67.3% of the cohort. The mean ages of the NPC and non-NPC patients were 54.2 and 61.9 years, respectively ($p<0.001$). There were significantly more young patients <45 years in the NPC group than in the non-NPC group (20.6% vs. 6.8%, $p<0.001$). More NPC than non-NPC patients received a combined modality of chemoRT (69.6% and 36.9%, $p<0.001$), with an RT dose ≥ 65 Gy (98.3% and 65.8%, $p<0.001$), and underwent a cisplatin regimen (63.7% and 30.4%, $p<0.001$). Given significant differences in the characteristics of NPC and non-NPC patients, subgroup analysis was conducted.

Prevalence of weight loss and predictive factors

A total of 288 patients (26.8%) had $\geq 10\%$ weight loss at the end of RT. The prevalence of $\geq 10\%$ weight loss increased from 2.8% before treatment to 32.7% after treatment in NPC patients and from 6.2% pretreatment to 13.5% after treatment in non-NPC patients (Table 2). In the NPC group, patients with $\geq 10\%$ weight loss, when compared with $<10\%$ weight loss, had a significantly higher proportion of men (80.2% vs. 71.3%, $p=0.009$), patients at a younger age <45 years old (26.3% vs. 17.8%, $p=0.018$), patients who lived alone (12.0% vs. 7.0%, $p=0.023$), patients with stage III–IV disease (75.7% vs. 62.5%, $p<0.001$), N+ (95.8% vs. 88.4%, $p<0.001$), chemoRT (87.2% vs. 60.7%, $p<0.001$), and cisplatin regimen (43.1% vs. 20.5%, $p=0.004$). In non-NPC, patients with $\geq 10\%$ weight loss contained a significantly higher proportion of men (88.9% vs. 73.4%, $p=0.024$), patients at an age of ≥ 75 years (2.2% vs. 11.8%, $p=0.018$), with stage III–IV disease (86.4% vs. 65.2% $p=0.005$), N+ (83.7% vs. 43.6%, $p<0.001$), chemoRT (86.7% vs. 29.1%, $p<0.001$), RT >65 Gy (97.8% vs. 61.6% $p<0.001$), and patients with no surgery (80.0% vs. 45.0%, $p<0.001$).

In NPC patients, multivariate logistic regression analysis yielded factors that were significantly associated with $\geq 10\%$ weight loss at the end of RT: age, living alone, use of cisplatin regimen, tube feeding, unplanned admissions, pretreatment BMI, and $>5\%$ weight loss at week 2 (Table 3). In non-NPC patients, multivariate logistic

Table 1 Demographic and patient characteristics of HNC patients undergoing RT with or without chemotherapy from 2011 to 2019 in Tune Mun Hospital

	Total		NPC		Non-NPC		<i>p</i> value
	<i>N</i>	%	<i>N</i>	%	<i>N</i>	%	
<i>N</i>	1086	100.0%	747	68.8%	339	31.2%	
Age (mean, SD)	56.6	12.1	54.2	11.9	61.9	10.8	0.000
Age (<i>N</i> , %)							
<45 years	177	16.3%	154	20.6%	23	6.8%	0.000
45–64 years	644	59.3%	464	62.1%	180	53.1%	
65–74 years	194	17.9%	94	12.6%	100	29.5%	
≥75 years	71	6.5%	35	4.7%	36	10.6%	
Smoking							
Smoker or ex-smoker	532	50.2%	323	44.6%	204	60.9%	0.000
Non-smoker	527	49.8%	401	55.4%	131	39.1%	
Alcohol consumption							
Drinker or ex-drinker	643	61.1%	235	32.7%	174	52.1%	0.000
Non-drinker	409	38.9%	483	67.3%	160	47.9%	
Living situation							
Live with family	958	88.6%	672	91.4%	286	86.9%	0.024
Live alone	106	9.8%	63	8.6%	43	13.1%	
Tumour site							
NPC	747	68.8%	747	100.0%			
Oropharynx	64	5.9%			64	18.9%	
Hypopharynx	31	2.9%			31	9.1%	
Larynx	99	9.1%			99	29.2%	
Oral cavity	90	8.3%			90	26.5%	
Sinus	9	0.8%			9	2.7%	
Salivary gland	37	3.4%			37	10.9%	
Nasal cavity	9	0.8%			9	2.7%	
Stage of disease							
Stage I–II	346	32.7%	247	33.1%	99	31.7%	0.673
Stage III–IV	713	67.3%	500	66.9%	213	68.3%	
T classification							
T1–2	526	49.9%	373	49.9%	153	49.7%	0.093
T3–4	529	50.1%	374	50.1%	155	50.3%	
N classification							
N0	281	26.7%	127	17.0%	154	50.2%	0.000
N+	773	73.3%	620	83.0%	153	49.8%	
Treatment modality							
RT alone	441	40.6%	227	30.4%	214	63.1%	0.000
ChemoRT	645	59.4%	520	69.6%	125	36.9%	
RT dose							
<65 Gy	129	11.9%	13	1.7%	116	34.2%	0.000
≥65 Gy	957	88.1%	734	98.3%	223	65.8%	
Induction chemotherapy							
No	861	79.3%	541	72.4%	320	94.4%	0.000
Yes	225	20.7%	206	27.6%	19	5.6%	
Chemotherapy regimen							
No cisplatin	66	10.2%	44	8.5%	22	17.6%	0.002
Cisplatin	579	89.8%	476	91.5%	103	82.4%	
Pretreatment BMI (mean, SD)	23.9	4.0	24.2	4.0	23.3	4.1	0.003
Pretreatment BMI							
<18.5 kg/m ²	67	6.2%	33	4.4%	34	10.0%	0.001

Table 1 (continued)

	Total		NPC		Non-NPC		<i>p</i> value
	<i>N</i>	%	<i>N</i>	%	<i>N</i>	%	
18.5–24.9 kg/m ²	628	57.9%	431	57.8%	197	58.1%	
≥25 kg/m ²	390	35.9%	282	37.8%	108	31.9%	

regression analysis demonstrated that factors significantly associated with ≥10% weight loss were RT dose ≥65 Gy, chemoRT, unplanned admissions, and weight loss >5% at week 2. In both NPC and non-NPC patients, weight loss >5% in week 2 of treatment was the strongest predictor of ≥10% weight loss at the end of treatment (OR 10.8, 95% CI 5.05–23.1 in NPC and OR 9.7, 95% CI 2.5–38.3 in non-NPC).

Weight loss and unplanned admissions

The prevalence of unplanned admissions in patients with ≥10% vs. <10% weight loss was 51.9% vs. 25.3% ($p<0.001$) in NPC patients and 68.9% vs. 27.0% ($p<0.001$) in non-NPC patients, respectively (Fig. 1, Appendix, Table 6). In both the NPC and non-NPC groups, unplanned admission was significantly higher in patients with ≥10% weight loss. A univariate analysis was conducted to assess the association between weight loss and unplanned admission.

In the NPC group, a significantly higher rate of unplanned admissions was observed in the following patients: those with stage III–IV disease, those who received induction chemotherapy, those on a cisplatin regimen, those with chemotherapy not given as planned, those who received a cisplatin dose of <200 mg/m², those with feeding tube placement, and those with weight loss of 5–10% at week 2. In the non-NPC group, there was a significantly higher prevalence of unplanned admissions in the following patients: those with stage III–IV disease, those with chemotherapy added, those with chemotherapy not given as planned, those with tube feeding, those with ≥2 dietitian consultations, and those with no surgery (Table 4).

These statistically significant factors in univariate analysis were entered into a multivariate analysis (Table 5). In NPC patients, multivariate logistic regression analysis showed that factors significantly associated with unplanned admissions were stage III–IV disease (OR 1.73, 95% CI 1.0–3.0, $p=0.049$), chemotherapy as planned (OR 0.61, 95% CI 0.39–0.97, $p=0.036$), feeding tube placement (OR 30.35, 95% CI 7.15–128.72, $p<0.001$), and ≥10% weight loss at the end of RT (OR 1.9, 95% CI 1.24–2.89, $p=0.003$). In non-NPC patients, multivariate logistic regression analysis showed that factors significantly associated with unplanned admissions were treatment modality of chemoRT (OR 6.34, 95% CI 3.04–13.22, $p<0.001$), chemotherapy as planned (OR 0.34, 95% CI 0.13–0.89, $p=0.034$), feeding

tube placement (OR 11.42, 95% CI 5.21–25.01, $p<0.001$), and weight loss >5% at week 2 (OR 2.67, 95% CI 1.09–6.55, $p=0.032$). In both NPC and non-NPC patients, feeding tube placement was the strongest independent predictor of unplanned hospital admissions.

Discussion

Our study aimed to investigate the association of weight loss and treatment interruptions, including RT delay, chemotherapy given as planned, cisplatin dose of ≥200 mg/m², and unplanned hospital admissions. Our study found that patients with weight loss of ≥10% had a significantly higher rate of unplanned hospital admissions but had no significant association with treatment interruptions.

Weight loss and treatment interruption (RT delay)

In our study, the prevalence of RT delay was 20.2% ($N=219$) for the whole cohort. The prevalence of RT delay ranged from 11.8 to 67% in previous studies [21, 32, 33]. This variation among studies might be related to the different definitions of RT delay and different disease entities included in various studies. In the subgroup analysis, we found that NPC patients had a significantly lower prevalence of RT delay than non-NPC patients (6.8% vs. 49.6%, $p=0.05$). This could likely be explained by the practice of RT schedule compensation for our NPC patients. In our centre, the RT schedule and progress of HNC patients were closely monitored. However, due to historical and logistical reasons, the facility was only able to accommodate special arrangements for NPC patients to catch up on any delays. It was not until 2019 that compensatory measures could also be arranged for non-NPC HNC patients.

Our study showed no significant association between weight loss and RT delay in either NPC or non-NPC patients. Previous studies investigating the association of weight loss and RT delay yielded conflicting results. Lindberg et al. reported that patients with HNC primary sites had the highest rate of RT interruptions among all cancer sites [34]. Likewise, patients with greater weight loss had significantly more RT interruptions and lower RT completion rates, as observed by another research group [35]. Studies have shown that weight loss with a change in body contour was one of the independent predictors for replanning

Table 2 Prevalence and characteristics of patient with weight loss

	NPC					Non-NPC				
	<10%		≥10%		<i>p</i> value	<10%		≥10%		<i>p</i> value
	<i>N</i>	%	<i>N</i>	%		<i>N</i>	%	<i>N</i>	%	
<i>N</i>	499	67.3%	243	32.7%		289	86.5%	45	13.5%	
% weight loss at week 7 (mean, SD)	−5.4	3.1	−13.1	2.8	0.000	−3.0	3.9	−12.9	2.4	0.000
Sex										
Male	356	71.3%	195	80.2%	0.009	212	73.4%	40	88.9%	0.024
Female	143	28.7%	48	19.8%		77	26.6%	5	11.1%	
Age										
<45 years	89	17.8%	64	26.3%	0.018	22	7.6%	1	2.2%	0.018
45–64 years	313	62.7%	147	60.5%		144	49.8%	33	73.3%	
65–74 years	69	13.8%	25	10.3%		89	30.8%	10	22.2%	
≥75 years	28	5.6%	7	2.9%		34	11.8%	1	2.2%	
Smoking										
Smoker	205	42.4%	115	48.7%	0.111	172	59.9%	27	62.8%	0.721
Nonsmoker	278	57.6%	121	51.3%		115	40.1%	16	37.2%	
Alcohol consumption										
Drinker	147	30.7%	86	36.8%	0.105	144	50.2%	26	61.9%	0.155
Non- or ex-drinker	332	69.3%	148	63.2%		143	49.8%	16	38.1%	
Living situation										
With family	454	93.0%	213	88.0%	0.023	243	87.1%	41	91.1%	0.447
Alone	34	7.0%	29	12.0%		36	12.9%	4	8.9%	
Stage of disease										
Stage I–II	187	37.5%	59	24.3%	0.000	92	34.8%	6	13.6%	0.005
Stage III–IV	312	62.5%	184	75.7%		172	65.2%	38	86.4%	
T classification										
T1–2	264	52.9%	108	44.4%	0.031	131	50.4%	21	48.8%	0.851
T3–4	235	47.1%	135	55.6%		129	49.6%	22	51.2%	
N classification										
N0	106	21.2%	20	8.2%	0.000	146	56.4%	7	16.3%	0.000
N+	393	78.8%	223	91.8%		113	43.6%	36	83.7%	
Treatment modality										
RT alone	196	39.3%	31	12.8%	0.000	205	70.9%	6	13.3%	0.000
ChemoRT	303	60.7%	212	87.2%		84	29.1%	39	86.7%	
Induction chemotherapy										
No	188	62.0%	132	62.3%	0.960	75	89.3%	30	76.9%	0.071
Yes	115	38.0%	80	37.7%		9	10.7%	9	23.1%	
Chemotherapy regimen										
No cisplatin	35	11.6%	9	4.2%	0.004	14	16.7%	8	20.5%	0.605
Cisplatin	268	88.4%	203	95.8%		70	83.3%	31	79.5%	
RT dose										
<65 Gy	10	2.0%	3	1.2%	0.453	111	38.4%	1	2.2%	0.000
≥65 Gy	489	98.0%	240	98.8%		178	61.6%	44	97.8%	
Surgery										
No surgery						130	45.0%	36	80.0%	0.000
Surgery						159	55.0%	9	20.0%	
Pretreatment BMI (mean, SD)	23.6	3.8	25.3	4.2	0.000	23.2	4.1	23.9	4.0	0.328
Pretreatment BMI										
<18.5	29	5.8%	4	1.6%	0.000	31	10.7%	3	6.7%	0.633
18.5–24.9	316	63.5%	112	46.1%		169	58.5%	26	57.8%	

Table 2 (continued)

	NPC					Non-NPC				
	<10%		≥10%		<i>p</i> value	<10%		≥10%		<i>p</i> value
	<i>N</i>	%	<i>N</i>	%		<i>N</i>	%	<i>N</i>	%	
≥25	153	30.7%	127	52.3%		89	30.8%	16	35.6%	
Pretreatment weight loss										
<5%	451	90.4%	214	88.1%	0.013	221	76.5%	37	82.2%	0.549
5–10%	40	8.0%	16	6.6%		51	17.6%	5	11.1%	
≥10%	8	1.6%	13	5.3%		17	5.9%	3	6.7%	
Weight loss 2 weeks										
<5%	479	97.8%	186	77.8%	0.000	278	97.2%	35	77.8%	0.000
5–10%	11	2.2%	50	20.9%		8	2.8%	10	22.2%	
≥10%	0	0.0%	3	1.3%		0	0.0%	0	0.0%	

Table 3 Multivariate logistic regression analysis of weight loss ≥10% at the end of RT

	<i>B</i>	S.E.	Wald	df	Sig.	Exp(<i>B</i>)	95% CI	
							Lower	Upper
a. NPC								
Age (<45 years as ref)			9.7	3	0.021			
Age (45–64 years)	−0.7	0.2	9.4	1	0.002	0.49	0.3	0.8
Age (65–74 years)	−0.7	0.4	4.1	1	0.042	0.49	0.2	1.0
Lives alone	0.7	0.3	4.6	1	0.032	1.97	1.1	3.7
Cisplatin regimen	1.2	0.2	24.6	1	0.000	3.37	2.1	5.5
Tube feeding	1.4	0.4	13.9	1	0.000	3.86	1.9	7.8
Unplanned admissions	0.5	0.2	5.1	1	0.024	1.60	1.1	2.4
BMI ≥25	2.1	0.7	10.8	1	0.001	8.52	2.4	30.7
Pretreatment weight loss ≥10%	1.3	0.5	6.1	1	0.014	3.55	1.3	9.7
>5% weight loss at week 2	2.4	0.4	37.6	1	0.000	10.81	5.1	23.1
Constant	−3.1	0.7	20.8	1	0.000	0.05		
b. Non-NPC								
RT dose ≥65 Gy	0.2	0.1	5.6	1	0.017	1.18	1.0	1.3
Chemotherapy added	1.8	0.5	11.2	1	0.001	6.24	2.1	18.3
>5% weight loss at week 2	2.3	0.7	10.5	1	0.001	9.70	2.5	38.2
Constant	−14.3	4.6	9.5	1	0.002	0.00		


[36, 37]. Significant weight loss could lead to anatomical changes and alter the external contour and position. This can potentially result in significant dosimetric changes in planning target volumes, and it can negatively affect treatment accuracy and increase toxicity [38–40].

Weight loss and unplanned admissions

A study showed that the rate of unplanned admissions in HNC patients was 65% [41]. Among studies performed on NPC patients, the incidence of unplanned admissions was between 20 and 36% [42, 43]. Our study revealed a significantly higher rate of unplanned admission in patients with ≥10% weight loss. These findings generally aligned with other studies. Duffy et al. reported that critical weight loss

of >5% was associated with a higher number of unplanned admissions in HNC patients undergoing chemoRT [9]. Capuano et al. reported a significantly higher rate of unplanned admissions in HNC patients with >20% weight loss, and weight loss was positively correlated with hospital admissions [44]. In a large cohort study on HNC surgical patients, Gourin et al. found that weight loss was significantly associated with postoperative complications, morbidities, and hospital length of stay [45]. In our non-NPC patients with >5% weight loss at week 2 of RT treatment, we found a significantly higher risk of unplanned admissions. We speculate that weight loss during the first few weeks of RT treatment predicts unplanned admissions, likely due to cumulative toxicity. If patients encounter symptoms early in their treatment journey, they are more likely to become intolerable to

Fig. 1 Prevalence of weight loss at the end of RT treatment in NPC and non-NPC patients with treatment interruptions (RT delay) and unplanned admissions



subsequent side effects and require hospitalization for side effect management.

Feeding tube placement and unplanned admissions In the present study, the strongest factor associated with unplanned admissions was feeding tube placement. Our non-NPC patients had a significantly higher rate of feeding tube placement (21.5%) than NPC patients (8.0%). This was likely related to the fact that many of our non-NPC patients already had their feeding tube placed after surgery or before treatment due to the early onset of eating-related symptoms prior to diagnosis. Studies on feeding tube placement and hospital admissions had mixed results. Brown et al. showed a lower incidence of unplanned admissions with prophylactic feeding tubes [46], and some reported no differences [47, 48]. Duffy et al. demonstrated a significantly higher risk of unplanned admissions with enteral feeding tube placement [9]. This variation in outcomes may be due to the timing of feeding tube placement and the availability of intensive supportive care. Nutrition status could be better preserved with prophylactic feeding tube placement, but admissions

for feeding tube complications were frequently observed [48]. In our centre, feeding tube placements were all performed in inpatient settings, and the majority of patients had reactive feeding tube insertions. For the majority of our HNC patients, by the time tube feeding is needed, they may already have developed profound toxicities, including those resulting in severe weight loss and requiring hospital admission for symptom management.

Concomitant chemoRT, cisplatin regimen, and unplanned admissions In our study, non-NPC patients with concomitant chemoRT had a significantly higher risk of unplanned admissions than patients with RT alone. Similarly, a study reported that patients with concomitant chemotherapy had a 3.96 times higher risk of unplanned admissions [49]. Nugent et al. reported that tube feeding was required for 66–71% of HNC patients on a combined treatment modality compared to only 12% of patients on a single modality of RT treatment [50]. Chemotherapy was found to be a major contributing factor for more clinic visits, a higher rate of RT interruption, more chemotherapy incompleteness, a greater need for tube

Table 4 Univariate analysis of weight loss and unplanned admissions (variables with $p < 0.05$)

	No admission		Admitted		<i>p</i> value
	<i>N</i>	%	<i>N</i>	%	
a. NPC					
Stage of disease					
Stage I–II	200	40.5%	47	18.6%	0.000
Stage III–IV	294	59.5%	206	81.4%	
Treatment modality					
RT alone	197	39.9%	30	6.1%	0.000
ChemoRT	297	60.1%	223	45.1%	
Induction chemotherapy					
No	376	76.1%	165	33.4%	0.002
Yes	118	23.9%	88	17.8%	
Feeding					
Oral	490	99.2%	197	77.9%	0.000
Tube feeding	4	0.8%	56	22.1%	
Weight loss at week 2					
<5%	458	93.9%	211	85.8%	0.001
5–10%	29	5.9%	33	13.4%	
≥10%	1	0.2%	2	0.8%	
Weight loss at week 7					
<10%	373	76.1%	126	50.0%	0.000
≥10%	117	23.8%	126	50.0%	
b. Non-NPC					
Stage of disease					
Stage I–II	83	39.7%	16	15.5%	0.000
Stage III–IV	126	60.3%	87	84.5%	
Treatment modality					
RT alone	177	77.3%	37	33.6%	0.000
ChemoRT	52	22.7%	73	66.4%	
Feeding					
Oral	215	93.9%	51	46.4%	0.000
Tube feeding	14	6.1%	59	53.6%	
Total no. of dietitian outpatient contacts					
≤1	17	7.4%	17	15.5%	0.021
≥2	212	92.6%	93	84.5%	
Weight loss at week 2					
<5%	220	97.8%	96	88.1%	0.000
5–10%	5	2.2%	13	11.9%	
≥10%		0.0%		0.0%	
Weight loss at week 7					
<10%	211	93.8%	78	71.6%	0.000
≥10%	14	6.2%	31	28.4%	
Surgery					
No surgery	104	45.4%	63	57.3%	0.041
Surgery	125	54.6%	47	42.7%	

feeding, and higher rates of complications and hospitalizations [51, 52]. Our results were consistent with these studies and showed that concomitant chemotherapy was associated with an increased rate of unplanned hospital admissions, greater weight loss, and tube feeding needs. Specifically, our NPC patients given a cisplatin regimen had a significantly higher risk and rate of unplanned admissions. Bright et al. reported that 23% of unplanned admissions for adverse effects were found in patients who received cisplatin regimens in various cancer types [53].

Prevalence of weight loss and its predictive factors

In the present study, the prevalence of ≥10% weight loss at the end of RT was 26.8%, and the prevalence was significantly higher in NPC patients (32.7%) than in non-NPC patients (13.5%) ($p < 0.001$).

Pretreatment weight loss Greater pretreatment weight loss in non-NPC patients can be explained partly by worse symptom exacerbation at the time of diagnosis. Non-NPC patients more often had a higher number of eating-related symptoms, including dysphagia, chewing difficulty, or airway obstruction, as their presenting symptoms. They commonly experienced issues with eating for a period of time, which already resulted in substantial pretreatment weight loss [54–56].

Posttreatment weight loss We observed less posttreatment weight loss in our non-NPC group. This might be due to the higher rate of feeding tube placement in these patients. In our practice, feeding tubes were often placed postoperatively in non-NPC patients and kept until the completion of adjuvant treatment. Patients with early commencement of tube feeding could have better preservation of nutrition status. In addition, more non-NPCs had a single modality of RT alone, and they commonly experienced less severe toxicities than those with concomitant chemoRT.

Age and weight loss Our results showed that younger patients had a significantly higher prevalence of ≥10% weight loss. This finding is consistent with previous studies [9, 57–62]. Some explanations include that younger patients often receive more aggressive treatment with substantially higher toxicities and are more physically active with higher energy expenditures. Interestingly, Monroe et al. reported that more nausea and vomiting were observed in younger patients, and the reason was not known [63].

BMI and weight loss Similar to other studies [58, 59, 64–70], our results showed that patients with higher BMI had significantly greater weight loss. Lønbro et al. reported a 5.1 times higher risk of >10% weight loss in HNC patients with BMI above 25 [58]. The reason for greater weight loss in patients

Table 5 Multivariate logistic regression analysis of weight loss and unplanned admissions

	<i>B</i>	S.E.	Wald	df	Sig.	Exp(<i>B</i>)	95% CI	
							Lower	Upper
a. NPC								
Stage III–IV	0.55	0.28	3.88	1	0.049	1.73	1.00	3.00
Chemotherapy as planned	−0.49	0.23	4.42	1	0.036	0.61	0.39	0.97
Tube feeding	3.41	0.74	21.43	1	0.000	30.35	7.15	128.72
≥10% weight loss at week 7	0.64	0.22	8.78	1	0.003	1.90	1.24	2.89
Constant	−1.05	0.28	13.78	1	0.000	0.35		
b. Non-NPC								
ChemoRT	1.85	0.38	24.26	1	0.000	6.34	3.04	13.22
Chemotherapy as planned	−1.08	0.50	4.79	1	0.029	0.34	0.13	0.89
Tube feeding	2.44	0.40	37.06	1	0.000	11.42	5.21	25.01
>5% weight loss at week 2	0.98	0.46	4.61	1	0.032	2.67	1.09	6.55
Constant	−2.32	0.28	67.13	1	0.000	0.10		

with high BMI might partly be due to the perception of better nutritional reserve, and consequently, reduced supportive care and less aggressive nutritional support were provided to these patients. de Oliveira Faria et al. reported that patients with obesity had been given less nutritional support when compared with that given to normal weight patients [70]. A study demonstrated that people with obesity experienced greater satisfaction from eating than normal weight adults [71]. When patients with obesity start to experience eating-related side effects, the joy of eating diminishes, and they become psychologically and emotionally distressed, eventually resulting in a substantial decrease in oral intake and subsequently causing significant weight loss.

Strengths and limitations

The main strength of this study is the large sample size with a representative sample of both NPC and non-NPC patients. This gives more reliable results with greater statistical power and precision. To the best of our knowledge, this is the first study investigating the association of weight loss with treatment outcomes and hospital admissions in an Asian population. This is also the first study that yielded differences in weight loss, treatment interruption, and unplanned hospital admissions between NPC and non-NPC patients.

This study has some limitations. First, there are intrinsic limitations of retrospective studies with potential selection bias. Second, both the methods and instruments used for the weight measurements were not standardized. This can affect measurement accuracy and affect the reliability

and validity of the data. Third, some important confounding factors, including patient performance status, quality of life status, comorbidity, and HPV status in oropharyngeal cancer, were either unavailable or not included. Fourth, during the selected period of 9 years, many new practices and advances in treatment modalities developed. Last, using BW as the sole nutritional indicator might not truly reflect patients' nutritional status, and the cause of weight loss is often multifactorial.

Conclusions

In our study, ≥10% weight loss was shown to be associated with a higher rate of unplanned hospital admissions in both NPC and non-NPC patients. Significant weight loss was not associated with RT delay or chemotherapy interruption in the present study. In NPC patients, factors significantly associated with unplanned admissions were stage III–IV disease, chemotherapy as planned, tube feeding placement, and ≥10% weight loss at the end of RT. In non-NPC patients, factors significantly associated with unplanned admissions were treatment modality of chemoRT, chemotherapy as planned, feeding tube, and weight loss >5% at week 2.

Clinical implications: This weight loss information assists in stratifying patients for intensive nutritional support. Our findings also support more targeted strategies to prevent unfavourable outcomes due to unplanned hospital admissions.

Appendix

Table 6 Prevalence of weight loss at the end of RT treatment in patients with treatment interruptions and unplanned admission

	NPC					Non-NPC				
	N	%	N	%	p value	N	%	N	%	p value
	<10%		≥10%			<10%		≥10%		
RT delay										
No Delay	464	93.0%	228	93.8%	0.668	143	49.5%	26	57.8%	0.300
Delayed	35	7.0%	15	6.2%		146	50.5%	19	42.2%	
Unplanned admission										
No admission	373	74.7%	117	48.1%	0.000	211	73.0%	14	31.1%	0.000
Admitted	126	25.3%	126	51.9%		78	27.0%	31	68.9%	

Acknowledgements Special thanks to Uta Schmidt-Straßburger for formatting and editing the original work, Jamie Chan for English language editing, Kenny Tse and Jeffery Lee for chemotherapy information, and Queenie Yuen and Ringo Sin for clerical support.

Author contribution CYC, TCL, PCC, and KWC contributed to the study conception and design. CYC and KLC participated in data collection and writing. CYC, JJH, and TCL participated in data analyses. CYC, JJH, JD, and TCL participated in data interpretation. CYC, KWC, PCC, JD, and TCL were involved in writing, reviewing, and editing the manuscript. TCL and JD provided supervision. The first draft of the manuscript was written by CYC, and all authors reviewed the manuscript and gave final approval for publication.

Declarations

Conflict of interest The authors declare no competing interests.

References

- Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. <https://gco.iarc.fr/>. Accessed on 31 August 2021
- Galbiatti AL, Padovani-Junior JA, Maniglia JV, Rodrigues CD, Pavarino EC, Goloni-Bertollo EM (2013) Head and neck cancer: causes, prevention and treatment. *Braz J Otorhinolaryngol* 79(2):239–247. <https://doi.org/10.5935/1808-8694.20130041>
- Cognetti DM, Weber RS, Lai SY (2008) Head and neck cancer: an evolving treatment paradigm. *Cancer* 113(7 Suppl):1911–1932. <https://doi.org/10.1002/cncr.23654>
- Lo Nigro C, Denaro N, Merlotti A, Merlano M (2017) Head and neck cancer: improving outcomes with a multidisciplinary approach. *Cancer Manag Res* 18(9):363–371. <https://doi.org/10.2147/CMAR.S115761>
- Jager-Wittenaar H, Dijkstra PU, Vissink A, van der Laan BF, van Oort RP, Roodenburg JL (2007) Critical weight loss in head and neck cancer—prevalence and risk factors at diagnosis: an explorative study. *Support Care Cancer* 15(9):1045–1050. <https://doi.org/10.1007/s00520-006-0212-9>
- Kubrak C, Martin L, Gramlich L, Scrimger R, Jha N, Debenham B, Chua N, Walker J, Baracos VE (2020) Prevalence and prognostic significance of malnutrition in patients with cancers of the head and neck. *Clin Nutr* 39(3):901–909. <https://doi.org/10.1016/j.clnu.2019.03.030>
- Oei RW, Ye L, Huang J, Kong F, Xu T, Shen C, Wang X, He X, Kong L, Hu C, Ying H (2018) Prognostic value of nutritional markers in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy: a propensity score matching study. *Oncotargets Ther* 11:4857–4868. <https://doi.org/10.2147/OTT.S165133>
- Zeng Q, Shen LJ, Guo X, Guo XM, Qian CN, Wu PH (2016) Critical weight loss predicts poor prognosis in nasopharyngeal carcinoma. *BMC Cancer* 16:169. <https://doi.org/10.1186/s12885-016-2214-4>
- Duffy AM, Halaki M, Spigelman A, Chin V, Gallagher RM, Flood VM (2020) Nutritional parameters associated with hospital admissions in patients being treated for head and neck cancer. *Support Care Cancer* 28(1):341–349. <https://doi.org/10.1007/s00520-019-04826-w>
- Cacicedo J, Dal Pra A, Alongi F, Navarro A (2015) Impact of weight loss in patients with head and neck carcinoma undergoing radiotherapy: is it an underestimated phenomenon? A radiation oncologist's perspective. *Eur J Clin Nutr* 69(7):757–760. <https://doi.org/10.1038/ejcn.2015.65>
- Langius JA, Bakker S, Rietveld DH, Kruijsenga HM, Langendijk JA, Weijs PJ, Leemans CR (2013) Critical weight loss is a major prognostic indicator for disease-specific survival in patients with head and neck cancer receiving radiotherapy. *Br J Cancer* 109(5):1093–1099. <https://doi.org/10.1038/bjc.2013.458>
- Ghadjar P, Hayoz S, Zimmermann F, Bodis S, Kaul D, Badakhshi H, Bernier J, Studer G, Plasswilm L, Budach V, Aebersold DM, Swiss Group for Clinical Cancer Research (SAKK) (2015) Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94). *Radiat Oncol* 10:21. <https://doi.org/10.1186/s13014-014-0319-y>
- Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, George JR, Barnes CA, Gourin CG, Der-Torossian H (2015) Cancer cachexia update in head and neck cancer: definitions and diagnostic features. *Head Neck* 37(4):594–604. <https://doi.org/10.1002/hed.23599>
- Einarsson S, Laurell G, Tiblom Ehrsson Y (2020) Mapping the frequency of malnutrition in patients with head and neck cancer using the GLIM Criteria for the Diagnosis of Malnutrition. *Clin Nutr ESPEN* 37:100–106. <https://doi.org/10.1016/j.clnesp.2020.03.011>

15. Andreyev HJ, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? *Eur J Cancer* 34(4):503–509. [https://doi.org/10.1016/s0959-8049\(97\)10090-9](https://doi.org/10.1016/s0959-8049(97)10090-9)
16. Lau SKM, Iyengar P (2017) Implications of weight loss for cancer patients receiving radiotherapy. *Curr Opin Support Palliat Care* 11(4):261–265. <https://doi.org/10.1097/SPC.0000000000000298>
17. Brown T, Banks M, Hughes BGM, Lin C, Kenny L, Bauer J (2017) Tube feeding during treatment for head and neck cancer - adherence and patient reported barriers. *Oral Oncol* 72:140–149. <https://doi.org/10.1016/j.oraloncology.2017.07.017>
18. Orell H, Schwab U, Saarilahti K, Österlund P, Ravasco P, Mäkitie A (2019) Nutritional counseling for head and neck cancer patients undergoing (chemo) radiotherapy-a prospective randomized trial. *Front Nutr* 6:22. <https://doi.org/10.3389/fnut.2019.00022>
19. Cotogni P, Pedrazzoli P, De Waele E, Aprile G, Farina G, Stragliotto S, De Lorenzo F, Caccialanza R (2019) Nutritional therapy in cancer patients receiving chemoradiotherapy: should we need stronger recommendations to act for improving outcomes? *J Cancer* 10(18):4318–4325. <https://doi.org/10.7150/jca.31611>
20. McCloskey SA, Jaggernauth W, Rigual NR, Hicks WL Jr, Popat SR, Sullivan M, Mashtare TL Jr, Khan MK, Loree TR, Singh AK (2009) Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. *Am J Clin Oncol* 32(6):587–591. <https://doi.org/10.1097/COC.0b013e3181967dd0>
21. Allal AS, de Pree C, Dulguerov P, Bieri S, Maire D, Kurtz JM (1999) Avoidance of treatment interruption: an unrecognized benefit of accelerated radiotherapy in oropharyngeal carcinomas? *Int J Radiat Oncol Biol Phys* 45(1):41–45. [https://doi.org/10.1016/s0360-3016\(99\)00138-8](https://doi.org/10.1016/s0360-3016(99)00138-8)
22. Barton MB, Keane TJ, Gadalla T, Maki E (1992) The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. *Radiother Oncol* 23(3):137–143. [https://doi.org/10.1016/0167-8140\(92\)90323-m](https://doi.org/10.1016/0167-8140(92)90323-m)
23. Meng L, Wei J, Ji R, Wang B, Xu X, Xin Y, Jiang X (2019) Effect of early nutrition intervention on advanced nasopharyngeal carcinoma patients receiving chemoradiotherapy. *J Cancer* 10(16):3650–3656. <https://doi.org/10.7150/jca.33475>
24. Waddle MR, Chen RC, Arastu NH, Green RL, Jackson M, Qaqish BF, Camporeale J, Collichio FA, Marks LB (2015) Unanticipated hospital admissions during or soon after radiation therapy: incidence and predictive factors. *Pract Radiat Oncol* 5(3):e245–e253. <https://doi.org/10.1016/j.prro.2014.08.004>
25. Paccagnella A, Morello M, Da Mosto MC, Baruffi C, Marcon ML et al (2010) Early nutritional intervention improves treatment tolerance and outcomes in head and neck cancer patients undergoing concurrent chemoradiotherapy. *Support Care Cancer* 18(7):837–845. <https://doi.org/10.1007/s00520-009-0717-0>
26. Hazzard E, Walton K, McMahon AT, Milosavljevic M, Tapsell LC (2018) Nutrition-related hospital presentations and admissions among radiotherapy outpatients: a systematic literature review. *J Hum Nutr Diet* 31(3):357–369. <https://doi.org/10.1111/jhn.12505>
27. Kono M, Wakisaka R, Kumai T, Hayashi R, Komatsuda H, Sato R, Abe Y, Yamaki H, Takahara M, Katada A, Hayashi T, Harabuchi Y (2021) Effects of early nutritional intervention by a nutritional support team for patients with head and neck cancer undergoing chemoradiotherapy or radiotherapy. *Head Neck* 43(2):514–519. <https://doi.org/10.1002/hed.26502>
28. Kiss NK, Krishnasamy M, Loeliger J, Granados A, Dutu G, Corry J (2012) A dietitian-led clinic for patients receiving (chemo) radiotherapy for head and neck cancer. *Support Care Cancer* 20(9):2111–2120. <https://doi.org/10.1007/s00520-011-1321-7>
29. National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) version 5. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed on 1 December 2021
30. World Health Organization. Regional Office for the Western Pacific. (2000) The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia. <https://apps.who.int/iris/handle/10665/206936>. Accessed on 1 December 2021.
31. The Royal College of Radiologists (2019) Timely delivery of radical radiotherapy: guidelines for the management of unscheduled treatment interruptions, fourth edition. <https://www.rcr.ac.uk/publication/timely-delivery-radical-radiotherapy-guidelines-management-unscheduled-treatment>. Accessed on 1 December 2021
32. Xu C, Zhang LH, Chen YP, Liu X, Zhou GQ, Lin AH, Sun Y, Ma J (2017) Chemoradiotherapy versus radiotherapy alone in *stage II* nasopharyngeal carcinoma: a systemic review and meta-analysis of 2138 patients. *J Cancer* 8(2):287–297. <https://doi.org/10.7150/jca.17317>
33. Kwong DL, Sham JS, Chua DT, Choy DT, Au GK, Wu PM (1997) The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 39(3):703–710. [https://doi.org/10.1016/s0360-3016\(97\)00339-8](https://doi.org/10.1016/s0360-3016(97)00339-8)
34. Lindberg RD, Jones K, Garner HH, Jose B, Spanos WJ Jr, Bhatnagar D (1988) Evaluation of unplanned interruptions in radiotherapy treatment schedules. *Int J Radiat Oncol Biol Phys* 14(4):811–815
35. Alhambra Expósito MR, Herrera-Martínez AD, Manzano García G, Espinosa Calvo M, Bueno Serrano CM, Gálvez Moreno MÁ (2018) Early nutrition support therapy in patients with head-neck cancer. *Nutr Hosp* 35(3):505–510
36. Hansen EK, Bucci MK, Quivey JM, Weinberg V, Xia P (2006) Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 64(2):355–362. <https://doi.org/10.1016/j.ijrobp.2005.07.957>
37. van Beek S, Jonker M, Hamming-Vrieze O, Al-Mamgani A, Navran A, Remeijer P, van de Kamer JB (2019) Protocolised way to cope with anatomical changes in head & neck cancer during the course of radiotherapy. *Tech Innov Patient Support Radiat Oncol* 12:34–40. <https://doi.org/10.1016/j.tipsro.2019.11.001>
38. Chen C, Fei Z, Chen L, Bai P, Lin X, Pan J (2014) Will weight loss cause significant dosimetric changes of target volumes and organs at risk in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy? *Med Dosim* 39(1):34–37. <https://doi.org/10.1016/j.meddos.2013.09.002>
39. Cheng HC, Wu VW, Ngan RK, Tang KW, Chan CC, Wong KH, Au SK, Kwong DL (2012) A prospective study on volumetric and dosimetric changes during intensity-modulated radiotherapy for nasopharyngeal carcinoma patients. *Radiother Oncol* 104(3):317–323. <https://doi.org/10.1016/j.radonc.2012.03.013>
40. Barker JL Jr, Garden AS, Ang KK, O'Daniel JC, Wang H, Court LE, Morrison WH, Rosenthal DI, Chao KS, Tucker SL, Mohan R, Dong L (2004) Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. *Int J Radiat Oncol Biol Phys* 59(4):960–970. <https://doi.org/10.1016/j.ijrobp.2003.12.024>

41. Lewis SL, Brody R, Touger-Decker R, Parrott JS, Epstein J (2014) Feeding tube use in patients with head and neck cancer. *Head Neck* 36(12):1789–1795. <https://doi.org/10.1002/hed.23538>
42. Sommat K, Yit NLF, Wang F, Lim JHC (2018) Impact of comorbidity on tolerability and survival following curative intent intensity modulated radiotherapy in older patients with nasopharyngeal cancer. *J Geriatr Oncol* 9(4):352–358. <https://doi.org/10.1016/j.jgo.2018.01.006>
43. Jagdis A, Laskin J, Hao D, Hay J, Wu J, Ho C (2014) Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC). *Am J Clin Oncol* 37(1):63–69. <https://doi.org/10.1097/COC.0b013e31826b9b1a>
44. Capuano G, Grosso A, Gentile PC, Battista M, Bianciardi F, Di Palma A, Pavese I, Satta F, Tosti M, Palladino A, Coiro G, Di Palma M (2008) Influence of weight loss on outcomes in patients with head and neck cancer undergoing concomitant chemoradiotherapy. *Head Neck* 30(4):503–508. <https://doi.org/10.1002/hed.20737>
45. Gourin CG, Couch ME, Johnson JT (2014) Effect of weight loss on short-term outcomes and costs of care after head and neck cancer surgery. *Ann Otol Rhinol Laryngol* 123(2):101–110. <https://doi.org/10.1177/0003489414523564>
46. Brown TE, Banks MD, Hughes BGM, Lin CY, Kenny LM, Bauer JD (2018) Comparison of nutritional and clinical outcomes in patients with head and neck cancer undergoing chemoradiotherapy utilizing prophylactic versus reactive nutrition support approaches. *J Acad Nutr Diet* 118(4):627–636. <https://doi.org/10.1016/j.jand.2016.10.013>
47. Bojaxhiu B, Shrestha BK, Luterbacher P, Elicin O, Shelan M, Macpherson AJS, Heimgartner B, Giger R, Aebersold DM, Zaugg K (2020) Unplanned hospitalizations in patients with locoregionally advanced head and neck cancer treated with (chemo)radiotherapy with and without prophylactic percutaneous endoscopic gastrostomy. *Radiat Oncol* 15(1):281. <https://doi.org/10.1186/s13014-020-01727-9>
48. Piquet MA, Ozsahin M, Larpin I, Zouhair A, Coti P, Monney M, Monnier P, Mirimanoff RO, Roulet M (2002) Early nutritional intervention in oropharyngeal cancer patients undergoing radiotherapy. *Support Care Cancer* 10(6):502–504. <https://doi.org/10.1007/s00520-002-0364-1>
49. Zachary R, Moore ZR, Pham NL, Shah JL, Nedzi L, Sumer BD, Day AT, Khan SA, Sher DJ (2019) Risk of unplanned hospital encounters in patients treated with radiotherapy for head and neck squamous cell carcinoma. *J Pain Symptom Manage* 57(4):738–745.e3. <https://doi.org/10.1016/j.jpainsymman.2018.12.337>
50. Nugent B, Parker MJ, McIntyre IA (2010) Nasogastric tube feeding and percutaneous endoscopic gastrostomy tube feeding in patients with head and neck cancer. *J Hum Nutr Diet* 23(3):277–284. <https://doi.org/10.1111/j.1365-277X.2010.01047.x>
51. Vulpe H, Ellis J, Huang SH, Atenafu EG, Jang RW, Rodin G, Ringash J (2017) The “rocky treatment course”: identifying a high-risk subgroup of head and neck cancer patients for supportive interventions. *Support Care Cancer* 25(3):719–727. <https://doi.org/10.1007/s00520-016-3450-5>
52. Givens DJ, Karnell LH, Gupta AK, Clamon GH, Pagedar NA, Chang KE, Van Daele DJ, Funk GF (2009) Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. *Arch Otolaryngol Head Neck Surg* 135(12):1209–1217. <https://doi.org/10.1001/archoto.2009.174>
53. Bright HR, Chandy SJ, Chacko RT, Backianathan S (2019) Intercycle unplanned hospital admissions due to cisplatin-based chemotherapy regimen-induced adverse reactions: a retrospective analysis. *Curr Drug Saf* 14(3):182–191. <https://doi.org/10.2174/1574886314666190619123047>
54. Larsson M, Hedelin B, Johansson I, Athlin E (2005) Eating problems and weight loss for patients with head and neck cancer: a chart review from diagnosis until one year after treatment. *Cancer Nurs* 28(6):425–435. <https://doi.org/10.1097/00002820-200511000-00004>
55. Motz K, Herbert RJ, Fakhry C, Quon H, Kang H, Kiess AP, Eisele DW, Koch WM, Frick KD, Gourin CG (2018) Short- and long-term outcomes of oropharyngeal cancer care in elderly individuals. *Laryngoscope* 128(9):2084–2093. <https://doi.org/10.1002/lary.27153>
56. Bressan V, Stevanin S, Bianchi M, Aleo G, Bagnasco A, Sasso L (2016) The effects of swallowing disorders, dysgeusia, oral mucositis and xerostomia on nutritional status, oral intake and weight loss in head and neck cancer patients: a systematic review. *Cancer Treat Rev* 45:105–119. <https://doi.org/10.1016/j.ctrv.2016.03.006>
57. Langius JA, Twisk J, Kampman M, Doornaert P, Kramer MH, Weijs PJ, Leemans CR (2016) Prediction model to predict critical weight loss in patients with head and neck cancer during (chemo) radiotherapy. *Oral Oncol* 52:91–96. <https://doi.org/10.1016/j.oraloncology.2015.10.021>
58. Lønbro S, Petersen GB, Andersen JR, Johansen J (2016) Prediction of critical weight loss during radiation treatment in head and neck cancer patients is dependent on BMI. *Support Care Cancer* 24(5):2101–2109. <https://doi.org/10.1007/s00520-015-2999-8>
59. Ottosson S, Zackrisson B, Kjellén E, Nilsson P, Laurell G (2013) Weight loss in patients with head and neck cancer during and after conventional and accelerated radiotherapy. *Acta Oncol* 52(4):711–718
60. Chang PH, Yeh KY, Huang JS, Chen EY, Yang SW, Wang CH (2015) Chemoradiotherapy in elderly patients with advanced head and neck cancer under intensive nutritional support. *Asia Pac J Clin Oncol* 11(3):228–235. <https://doi.org/10.1111/ajco.12323>
61. Ding H, Dou S, Ling Y, Zhu G, Wang Q, Wu Y, Qian Y (2018) Longitudinal body composition changes and the importance of fat-free mass index in locally advanced nasopharyngeal carcinoma patients undergoing concurrent chemoradiotherapy. *Integr Cancer Ther* 17(4):1125–1131. <https://doi.org/10.1177/1534735418807969>
62. Nazari V, Pashaki AS, Hasanzadeh E (2021) The reliable predictors of severe weight loss during the radiotherapy of head and neck cancer. *Cancer Treat Res Commun* 26:100281. <https://doi.org/10.1016/j.ctarc.2020.100281>
63. Monroe AT, Reddy SC, Gibbs GL, White GA, Peddada AV (2008) Factors associated with radiation-induced nausea and vomiting in head and neck cancer patients treated with intensity modulated radiation therapy. *Radiat Oncol* 87(2):188–194
64. Yang YC, Lee MS, Cheng HL, Chou HY, Chan LC (2019) More frequent nutrition counselling limits weight loss and improves energy intake during oncology management: a longitudinal inpatient study in Taiwan. *Nutr Cancer* 71(3):452–460. <https://doi.org/10.1080/01635581.2018.1516791>
65. Li G, Jiang XY, Qiu B, Shen LJ, Chen C, Xia YF (2017) Vicious circle of acute radiation toxicities and weight loss predicts poor prognosis for nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. *J Cancer* 8(5):832–838. <https://doi.org/10.7150/jca.17458>
66. Du XJ, Tang LL, Mao YP, Guo R, Sun Y, Lin AH, Ma J (2015) Value of the prognostic nutritional index and weight loss in

- predicting metastasis and long-term mortality in nasopharyngeal carcinoma. *J Transl Med* 13:364
67. Qiu C, Yang N, Tian G (2011) Liu H (2011) Weight loss during radiotherapy for nasopharyngeal carcinoma: a prospective study from northern China. *Nutr Cancer* 63(6):873–879. <https://doi.org/10.1080/01635581.2011.582223>
 68. Vlooswijk CP, van Rooij PH, Kruize JC, Schuring HA, Al-Mamgani A, de Roos NM (2016) Dietary counselling and nutritional support in oropharyngeal cancer patients treated with radiotherapy: persistent weight loss during 1-year follow-ups. *Eur J Clin Nutr* 70(1):54–59. <https://doi.org/10.1038/ejcn.2015.102>
 69. Lee SC, Wang TJ, Chu PY (2019) Predictors of weight loss during and after radiotherapy in patients with head and neck cancer: a longitudinal study. *Eur J Oncol Nurs* 39:98–104. <https://doi.org/10.1016/j.ejon.2019.02.004>
 70. de Oliveira FS, Howell D, Vamondes Kulcsar MA, Eluf-Neto J (2020) Nutritional outcomes in head and neck cancer patients: is intensive nutritional care worth it? *Cancer Treat Res Commun* 25:100233. <https://doi.org/10.1016/j.ctarc.2020.100233>
 71. Miller AC, Polgreen LA, Segre EM, Polgreen PM (2020) Variations in marginal taste perception by body mass index classification: a randomized controlled trial. *J Acad Nutr Diet* 120(1):45–52. <https://doi.org/10.1016/j.jand.2019.05.018>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.